China Blood Product Industry Report, 2016-2019

8/20/2019 China Blood Product Industry Report, 2016-2019

http://slidepdf.com/reader/full/china-blood-product-industry-report-2016-2019 1/15

China Blood Product Industry Report,

2016-2019

Mar. 2016



ME!"#"$"%&

Both primary and secondary research methodologies were used

in preparing this study. Initially, a comprehensive and exhaustive

search of the literature on this industry was conducted. These

sources included related books and journals, trade literature,

marketing literature, other product/promotional literature, annual

reports, security analyst reports, and other publications.

ubse!uently, telephone interviews or email correspondence

was conducted with marketing executives etc. "ther sources

included related maga#ines, academics, and consulting

companies.

I'("RM)I"' *"+RCE*

The primary information sources include $ompany %eports,and &ational Bureau of tatistics of $hina etc.

*+#& %")$ )'# "BECIE*

This report provides the industry executives with strategically significant

competitor information, analysis, insight and projection on the

competitive pattern and key companies in the industry, crucial to the

development and implementation of effective business, marketing and

%'( programs.

REP"R "BECIE* To establish a comprehensive, factual, annually updated and cost)

effective information base on market si#e, competition patterns,

market segments, goals and strategies of the leading players in the

market, reviews and forecasts.

To assist potential market entrants in evaluating prospective

ac!uisition and joint venture candidates.

To complement the organi#ations* internal competitor information

gathering efforts with strategic analysis, data interpretation and

insight.

To suggest for concerned investors in line with the current

development of this industry as well as the development tendency.

To help company to succeed in a competitive market, and

understand the si#e and growth rate of any opportunity.

%oom +-, Block , Tower $, $hangyuan Tiandi Building, &o. 0, u#hou treet, 1aidian (istrict, Beijing, $hina 0

2hone3 405 0-50-0 6 7ax3 405 0-5+8 6 www.researchinchina.com 6 report9researchinchina.com

$opyright -- %esearchIn$hina



)stract

%ecombinant blood products have developed for many years in foreign countries, but $hina*s blood products are still proteins extracted from

human blood. Thus, reserves and control of plasma resources are the key to the development of $hinese blood product enterprises. :mid

the industrial prosperity and favorable policies, $hina had more than ; plasma collection stations with the production)use plasma volume

of <, 8 tons and the total lot release volume jumped by .5 million bottles year on year to ++.85 million bottles in -+.

=iven stringent re!uirements on new domestic plasma stations, hanghai %::, $hina Biologic 2roducts >handong Taibang and =ui#hou

Taibang?, 1ualan Biological @ngineering, Tiantan Biological >including $hengdu %ongsheng? and Auanda huyang which boast abundantcapital, powerful %'( strength and rich plasma station resources have become the top five companies in $hina blood product industry,

contributing 5.; to $hina*s production)use plasma volume in -+.

7rom the point of view of the product structure, human albumin is still the largest type of blood products in $hina, but its supply has slowed down

with a lower contribution +0.0 to $hina*s total blood product lot release volume in -+. In recent years, the rising lot release volume of

$hinese human albumin is mainly attributed to ample supply of imported products. In -)-+, the lot release volume of human albumin

imported by $hina grew at a $:=% of -.8, accounting for as much as ++.5 of the total. $hinaCs top four human albumin import

enterprises ))) Behring, Baxter, =rifols and "ctapharma sei#ed +.8 of the total lot release volume in -+.

$hinaCs second largest type of blood products )) human immunoglobulin >ph<? for intravenous injection saw its lot release volume jump by .+year on year to ;.< million bottles >-.+g / bottle? and its share increase to 5.; in -+. "ver the same period, tetanus human

immunoglobulin, hepatitis B immune globulin and other immune globulin products and coagulation factor products witnessed growth in lot

release volume except human rabies immunoglobulin whose lot release volume declined slightly.

The research and development of human blood coagulation factor DIII, human prothrombin complex and other small products in rigid demand

has made the most remarkable progress in recent years. $oncerning human blood coagulation factor DIII, hanghai Einxing had been

approved to launched its human blood coagulation factor DIII, hen#hen Feiguang had entered the new drug registration stage, =uangdong

huanglin Bio)2harmacy had embarked on trial production, Giangxi Boya Bio)2harmaceutical had gone into clinical phase III >the

industriali#ation is expected in 1- -5?, Fuhan Hhongyuan %uide had obtained clinical approval and 1arbin 2acific Biopharmaceutical hadapplied for clinical approval by the end of -+.



$opyright --%esearchIn$hina



In order to possess and effectively use plasma raw materials, enterprises are more willing to cooperate mutually in addition to ac!uisition. In

:ugust -+, $hina Biologic 2roducts and Einjiang (eyuan signed a strategic cooperation agreement, under which the former should purchaseat least -/0/- tons of plasma from the latter per year in the next three years. In -+, 1ebei (a*an 2harmaceutical and =uangdong

Feilun actively planned to cooperate on the allocation of plasma fraction II 4 III, namely the former >it only produces human albumin now? should

allocate partial plasma fraction II 4 III to =uangdong Feilun for the production of immunoglobulin products.

$hina Blood 2roduct Industry %eport, -5)-; focuses on the followings3 arket characteristics, operating environments, status !uo, etc. of $hina blood product industryJ upply and demand, competition pattern, import and export, development forecast, etc. of $hina blood product industryJ upply and demand, competition pattern, etc. of 0 blood product segments, including human albumin, human immunoglobulin >p1<? for

intravenous injection, blood coagulation factor and tetanus human immunoglobulinJ

"peration, blood product business and prospects of major $hinese blood product companies.



$opyright --%esearchIn$hina



1. "/er/ie o Blood Product Industry

. (efinition.- $lassification

. %ecombinant Blood 2roducts

.< Industry $hain

.+ 7eatures

2. "/er/ie o China Blood Product Industry

-. arket i#e

-.- tatus Kuo

-. upply and (emand

-.. upply

-..- (emand

-.< $ompetition

-.+ "perating @nvironment

-.+. International

-.+.- 2olicy

-.+. (omestic Biopharmaceutical arket

-.5 Import and @xport

. Blood Product Mar3et *e45ents in China

. 1uman :lbumin

.. upply and (emand

..- $ompetition 2attern

.. 2rospects

.- 1uman Immunoglobulin >p1<? for Intravenou

s Injection

Table of contents

Roo5 02, Bloc3 , oer C, Chan4yuan iandi Buildin4, 'o. 17, *u8hou *treet, !aidian #istrict, Beiin4, China 100070

Phone: ;76 10 72600727 < (a=: ;76 10 72601>0 < .researchinchina.co5 < report?researchinchina.co5

.-. upply and (emand

.-.- $ompetition 2attern. Blood $oagulation 7actor DIII

.. upply and (emand

..- $ompetition 2attern

.. 2rospects

.< 1epatitis B Immunoglobulin

.<. upply and (emand

.<.- $ompetition 2attern

.+ 1uman Immunoglobulin

.+. upply and (emand

.+.- $ompetition 2attern

.5 1uman 2rothrombin $omplex

.5. upply and (emand

.5.- $ompetition 2attern

.8 Tetanus Immunoglobulin

.8. upply and (emand


.0 1uman %abies Immunoglobulin.0. upply and (emand


@. Maor Chinese Manuacturers

<. $hina Biologic 2roducts Inc. >&:(:K3 $B2"?

<.. 2rofile

<..- "peration

<.. %evenue tructure

<..< $ustomers and uppliers

<..+ %'( and Investment<..5 handong Taibang Biological 2roducts $o., Ltd.

<..8 =ui#hou Taibang Biological 2roducts $o., Ltd.

<..0 EiCan 1uitian Blood 2roducts $o., Ltd.

<..; "utlook and 2rospects

<.- 1ualan Biological @ngineering Inc. >-8.H?

<.-. 2rofile

<.-.- "peration

<.-. %evenue tructure

<.-.< =ross argin

<.-.+ $ustomers and uppliers

<.-.5 %'( and Investment

<.-.8 Blood 2roducts

<.-.0 "utlook and 2rospects

<. hanghai %:: Blood 2roducts $o., Ltd. >--+-

.H?

<.. 2rofile

<..- "peration

<.. %evenue tructure

<..< =ross argin

<..+ $ustomers and uppliers

<..5 %'( and Investment

<..8 "utlook and 2rospects

<.< Beijing Tiantan Biological 2roducts $o., Ltd. >TI:&

T:&BI", 55.1?

<.<. 2rofile



<.<.- "peration

<.<. %evenue tructure<.<.< $ustomers and uppliers

<.<.+ =ross argin

<.<.5 %'( and Investment

<.<.8 Blood 2roducts >$hengdu %ongsheng 2harmac

eutical $o., Ltd.?

<.<.0 "utlook and 2rospects

<.+ Hhenxing Biopharmaceutical and $hemical $o., Lt

d. ><.H?

<.+. 2rofile

<.+.- "peration

<.+. %evenue tructure

<.+.< =ross argin

<.+.+ $ustomers and uppliers

<.+.5 %'( and Investment

<.+.8 Blood 2roducts >=uangdong huanglin Bio)

2harmacy $o., Ltd.?

<.+.0 "utlook and 2rospects

<.5 Giangxi Boya Bio)

2harmaceutical $o., Ltd. >-;<.H?

<.5. 2rofile

<.5.- "peration

<.5. %evenue tructure

<.5.< =ross argin

<.5.+ $ustomers and uppliers

<.5.5 %'( and Investments

Table of contents

Roo5 02, Bloc3 , oer C, Chan4yuan iandi Buildin4, 'o. 17, *u8hou *treet, !aidian #istrict, Beiin4, China 100070

Phone: ;76 10 72600727 < (a=: ;76 10 72601>0 < .researchinchina.co5 < report?researchinchina.co5

<.5.8 "utlook and 2rospects

<.8 ichuan Auanda huyang 2harmaceutical $o., Ltd.<.8. 2rofile

<.8.- Blood 2roducts

<.0 hanghai Institute of Biological 2roducts $o., Ltd.

<.0. 2rofile

<.0.- Blood 2roducts

<.; hanxi Mangbao Biological 2roduct $o., Ltd.

<.;. 2rofile

<.;.- Blood 2roducts

<. =reen $ross

<.. 2rofile

<..- Blood 2roducts

<. 1umanwell 1ealthcare =roup $o., Ltd. >58;.1?

<.. 2rofile

<..- "peration

<.. Blood 2roducts >Fuhan Hhongyuan %uide Biological 2roduct $o., Ltd.?

<.- Falvax Biotechnology $o, Ltd. ><-.H?

<.-. 2rofile

<.-.- "peration

<.-. Blood 2roducts >1ebei (a*an 2harmaceutical $o., Ltd. and =uangdong

Feilun Biological 2harmaceutical $o., Ltd.?

<. hen#hen Feiguang Biological 2roducts $o., Ltd.

. *u55ary and (orecast

+. $ompany :nalysis

+.- =rowth 2rediction



N Basic $omponents of BloodN 2lasma 2rotein eparation 2rocedure

N $lassification and 7unction of Blood 2roducts

N $omparison between =ene %ecombinant Blood 2roducts and Traditional Blood 2roducts

N $omparison between (omestic and 7oreign %ecombinant Blood 2roducts in Types

N Blood 2roduct Industry $hain

N Time $onsumption of 2lasma $ollection and eparation 2rocess

N $omparison between Blood 2roduct @nterprises and $hemical ' 2harmaceutical @nterprises in "perating $osts and @xpenses

N 2rices of ome Blood 2roducts in $hina, -<

N Blood 2roduct arket i#e in $hina, -)-+

N Lot %elease Dolume of Blood 2roducts in $hina >by 2roduct?, -;)-+

N Blood 2roduct tructure in $hina >by Lot %elease Dolume?, -;)-+

N 2er $apita 7re!uency of 2lasma (onation and 2lasma $ollection in $hina vs. the "ccident

N 2lasma $ollections in $hina vs. O:

N 2roduction)use 2lasma Dolume in $hina, -0)-+

N &umber of 2lasma $ollection tations in $hina, -0)-+

N =eographical (istribution of 2lasma tation %esources in $hina by the @nd of -+N ainstream Blood 2roducts with edical Insurance $overage in $hina

N 2er $apita $onsumption of Blood 2roducts in $hina vs. (eveloped $ountries

N 2lasma tation (istribution, 2roduction)use 2lasma Dolume and Blood 2roduct %evenue of ajor Blood 2roduct @nterprises in $hina, -<

N 2lasma tation (istribution, 2roduction)use 2lasma Dolume and Blood 2roduct %evenue of ajor Blood 2roduct @nterprises in $hina, -+

N $omparison of $hinese Blood 2roduct anufacturing @nterprises in 2roduct Line

N $ompetition 2attern of =lobal Blood 2roduct @nterprises, -

Selected Charts





N 2roduct tructure of =lobal Blood 2roducts

N Blood 2roducts :vailable in "verseas arket

N =lobal Blood 2roduct anufacturers

N ain 2olicies on $hinese Blood 2roducts

N 2olicies on aximum %etail 2rice of (rugs in $hina, -<)-+

N Lot %elease Dolume of Imported 1uman :lbumin in $hina, -0)-+

N :verage 1uman :lbumin 2urchase 2rice of ample 1ospitals in $hina, -+)-<

N 2roportion of (omestic and Imported 1uman :lbumin in $hina >by Lot %elease Dolume?, -8)-+

N arket hare of ajor 1uman :lbumin anufacturers in $hina >by Lot %elease Dolume?, -0)-+

N $onsumption of 1uman Immunoglobulin >p1<? for Intravenous Injection per , 2ersons by $ountry, - >g/, persons?

N Lot %elease Dolume and =rowth %ate of 1uman Immunoglobulin >p1<? for Intravenous Injection in $hina, -8)-+

N 2rice of 1uman Immunoglobulin >p1<? for Intravenous Injection in $hina vs. "ther $ountries

N :verage 2urchase 2rice of 1uman Immunoglobulin >p1<? for Intravenous Injection of ample 1ospitals in $hina, -+)-<

N arket hare of ajor anufacturers of 1uman Immunoglobulin >p1<? for Intravenous Injection in $hina >by Lot %elease Dolume?, -8)-+

N Lot %elease Dolume and =rowth %ate of Blood $oagulation 7actor DIII in $hina, -0)-+

N arket hare of ajor 1uman Blood $oagulation 7actor DIII anufacturers in $hina >by Lot %elease Dolume?, -0)-+

N $omparison between 1uman Blood $oagulation 7actor DIII and %ecombinant Blood $oagulation 7actor DIIIN 2er $apita $onsumption of %ecombinant DIII 7actor and 2lasma DIII 7actor in ajor $ountries >IO/2erson?

N Lot %elease Dolume and =rowth %ate of 1epatitis B Immunoglobulin in $hina, -;)-+

N arket hare of ajor 1epatitis B Immunoglobulin anufacturers in $hina >by Lot %elease Dolume?, -0)-+

N 2rices of 1uman Immunoglobulin in $hina by (osage, -<

N Lot %elease Dolume and =rowth %ate of 1uman Immunoglobulin in $hina, -0)-+

N arket hare of ajor 1uman Immunoglobulin anufacturers in $hina >by Lot %elease Dolume?, -0)-+

N Lot %elease Dolume and =rowth %ate of 1uman 2rothrombin $omplex in $hina, -0)-+

Selected Charts





N arket hare of ajor 1uman 2rothrombin $omplex anufacturers in $hina >by Lot %elease Dolume?, -0)-+

N Lot %elease Dolume and =rowth %ate of Tetanus Immunoglobulin in $hina, -0)-+

N arket hare of ajor Tetanus Immunoglobulin anufacturers in $hina >by Lot %elease Dolume?, -0)-+

N %abies Incidents and (eath %ate in $hina, -0)-<

N Lot %elease Dolume and =rowth %ate of 1uman %abies Immunoglobulin in $hina, -0)-+

N arket hare of ajor 1uman %abies Immunoglobulin anufacturers in $hina >by Lot %elease Dolume?, -0)-+

N @!uity tructure of $hina Biologic 2roducts by the @nd of -<

N (istribution of Blood 2roducts anufacturing Bases and 2lasma tations of $B2", -+

N %evenue and "perating Income of $B2", -0)-+

N =ross argin of $B2", -)-+N %evenue Breakdown of $B2" >by 2roduct?, -)-+

N %evenue tructure of $B2" >by 2roduct?, -)-+

N $B2"*s %evenue from Top + $ustomers and of Total %evenue, -0)-<

N %'( $osts and of Total %evenue of $B2", -)-+

N Lot %elease Dolume of Blood 2roducts of handong Taibang Biological 2roducts, -0)-+

N Lot %elease Dolume of Blood 2roducts of =uiyang Kianfeng Biological 2roducts, -0)-+

N Lot %elease Dolume of Blood 2roducts of EiCan 1uitian Blood 2roducts, -0)-<

N %evenue and "perating Income of $B2", -<)-;@N %evenue and "perating Income of 1ualan Biological @ngineering Inc., -0)-+

N %evenue of 1ualan Biological @ngineering Inc. >by ector?, -0)-+

N =ross argin of 1ualan Biological @ngineering Inc. >by 2roduct?, -0)-+

N 1ualan Biological @ngineering Inc.*s %evenue from Top + $ustomers and of Total %evenue, -8)-<

N 1ualan Biological @ngineering Inc.*s 2rocurement from Top + uppliers and of Total 2rocurement, -8)-<

N &ame List and 2rocurement $ontribution of 1ualan Biological @ngineering Inc.*s Top + uppliers, -<

N %'( $osts and of Total %evenue of 1ualan Biological @ngineering Inc., -0)-+

Selected Charts





N Types and pecifications of Blood 2roducts of 1ualan Biological @ngineering Inc.

N (istribution of 2lasma $ollection tations of 1ualan Biological @ngineering Inc. by the @nd of -+

N Lot %elease Dolume of Blood 2roducts of 1ualan Biological @ngineering Inc., -0)-+

N %evenue and =ross argin of Blood 2roducts of 1ualan Biological @ngineering Inc., -0)-+

N %evenue and =ross argin of Blood 2roducts of 1ualan Biological @ngineering Inc. >by 2roduct?, -0)-+

N %evenue and "perating Income of 1ualan Biological @ngineering Inc., -<)-;@

N hanghai %::*s ubsidiaries and Their "peration, 1 -+ >%B mln?

N (istribution of 2lasma tations of hanghai %:: by the @nd of -+

N %evenue and "perating Income of hanghai %::, -0)-+

N Lot %elease Dolume of Blood 2roducts of hanghai %::, -0)-+N Lot %elease Dolume of Blood 2roducts of Tonrol Bio)2harmaceutical, -0)-+

N "perating %evenue of hanghai %:: >by 2roduct?, -0)-+

N %evenue of hanghai %:: >by %egion?, -0)-+

N =ross argin of hanghai %:: >by 2roduct?, -0)-+

N hanghai %::*s %evenue from Top + $ustomers and of Total %evenue, -0)-+

N hanghai %::*s 2rocurement from Top + uppliers and of Total 2rocurement, -8)-<

N %'( $osts and of Total %evenue of hanghai %::, -0)-+

N %evenue and "perating Income of hanghai %::, -<)-;@N TI:&T:&BI"*s ubsidiaries and Their %evenue and Income, 1 -+ >%B mln?

N %evenue and "perating Income of TI:&T:&BI", -0)-+

N %evenue of TI:&T:&BI" >by ector?, -0)-+

N %evenue of TI:&T:&BI" >by %egion?, -0)-+

N TI:&T:&BI"*s 2rocurement from Top + uppliers and of Total 2rocurement, -0)-<

N TI:&T:&BI"*s %evenue from Top + $ustomers and of Total %evenue, -0)-<

N =ross argin of TI:&T:&BI" >by ector?, -0)-+

Selected Charts





N %'( $osts and of Total %evenue of TI:&T:&BI", -;)-+

N (istribution of 2lasma $ollection tations of TI:&T:&BI" by the @nd of -+

N %evenue and =ross argin of Blood 2roducts of TI:&T:&BI", -0)-+

N Lot %elease Dolume of Blood 2roducts of %onen and TI:&T:&BI", -0)-+

N %evenue and "perating Income of TI:&T:&BI", -<)-;@

N %evenue and "perating Income of Hhenxing Biopharmaceutical and $hemical, -0)-+

N "perating %evenue of Hhenxing Biopharmaceutical and $hemical >by 2roduct?, -;)-+

N =ross argin of Hhenxing Biopharmaceutical and $hemical >by 2roduct?, -;)-

N Hhenxing Biopharmaceutical and $hemical*s %evenue from Top + $ustomers and of Total %evenue, -;)-<

N &ame List and %evenue $ontribution of Hhenxing Biopharmaceutical and $hemical*s Top + $ustomers, -<N Hhenxing Biopharmaceutical and $hemical*s 2rocurement from Top + uppliers and of Total 2rocurement, -<

N %'( $osts and of Total %evenue of Hhenxing Biopharmaceutical and $hemical, -;)-+

N 2roduction)use 2lasma Dolume of huanglin Bio)2harmacy, -)-+

N (istribution of 2lasma $ollection tations of huanglin Bio)2harmacy by the @nd of -+

N Lot %elease Dolume of Blood 2roducts of huanglin Bio)2harmacy, -0)-+

N %evenue and =ross argin of Blood 2roducts of Hhenxing Biopharmaceutical and $hemical, -;)-+

N %evenue and "perating Income of Hhenxing Biopharmaceutical and $hemical, -<)-;@

N (istribution of ingle 2lasma $ollection tations of Giangxi Boya Bio)2harmaceutical by the @nd of -+N 2lasma $ollection Dolume of Giangxi Boya Bio)2harmaceutical, -0)-+

N %evenue and "perating Income of Giangxi Boya Bio)2harmaceutical, -0)-+

N %evenue of Giangxi Boya Bio)2harmaceutical >by 2roduct?, -;)-+

N Lot %elease Dolume of ajor Blood 2roducts of Giangxi Boya Bio)2harmaceutical, -)-<

N "perating %evenue of Giangxi Boya Bio)2harmaceutical >by %egion?, -;)-<

N =ross argin of Giangxi Boya Bio)2harmaceutical >by 2roduct?, -;)-+

N Giangxi Boya Bio)2harmaceutical*s %evenue from Top + $ustomers and of Total %evenue, -;)-+

Selected Charts





N Giangxi Boya Bio)2harmaceutical*s 2rocurement from Top + uppliers and of Total 2rocurement, -;)-+

N %'( $osts and of Total %evenue of Giangxi Boya Bio)2harmaceutical, -;)-+

N 2roducts under %esearch and 2rogress of Giangxi Boya Bio)2harmaceutical as of "ct. -+

N %evenue and "perating Income of Giangxi Boya Bio)2harmaceutical, -<)-;@

N (istribution of 2lasma tations of ichuan Auanda huyang 2harmaceutical by the @nd of -+

N Lot %elease Dolume of Blood 2roducts of ichuan Auanda huyang 2harmaceutical, -0)-+

N Lot %elease Dolume of Blood 2roducts of hanghai Institute of Biological 2roducts, -0)-+

N (istribution of 2lasma tations of hanghai Institute of Biological 2roducts by the @nd of -+

N (istribution of 2lasma tations of hanxi Mangbao Biological 2roduct by the @nd of -+

N Lot %elease Dolume of Blood 2roducts of hanxi Mangbao Biological 2roduct, -0)-+N (istribution of 2lasma tations of =reen $ross $hina by the @nd of -+

N Lot %elease Dolume of Blood 2roducts of =reen $ross $hina, -0)-+

N %evenue and "perating Income of 1umanwell 1ealthcare, -;)-+

N Lot %elease Dolume of Blood 2roducts of Fuhan Hhongyuan %uide Biological 2roduct, -0)-+

N 2roduction Industry Layout of Falvax Biotechnology

N %evenue and "perating Income of Falvax Biotechnology, -;)-+

N %evenue of Falvax Biotechnology >by 2roduct?, -;)-+

N (istribution of ingle 2lasma $ollection tations of hen#hen Feiguang Biological 2roducts by the @nd of -+N 2lasma $ollection Dolume and 2roduction)use 2lasma Dolume of hen#hen Feiguang Biological 2roducts, --)-+

N %evenue and "perating Income of hen#hen Feiguang Biological 2roducts, --)-+

N $apacity, 2roduction and ales Dolume of hen#hen Feiguang Biological 2roducts >by 2roduct?, --)-+

N %evenue Breakdown of hen#hen Feiguang Biological 2roducts >by 2roduct?, --)-+ >%B mln?

N %evenue tructure of hen#hen Feiguang Biological 2roducts >by 2roduct?, --)-+ >%B mln?

N =ross argin of hen#hen Feiguang Biological 2roducts >by 2roduct?, --)-+

N &ame List and %evenue $ontribution of hen#hen Feiguang Biological 2roducts* Top + $ustomers, --)-+

Selected Charts





N &ame List and 2rocurement $ontribution of hen#hen Feiguang Biological 2roducts* Top + uppliers, --)-+

N %'( $osts and of Total %evenue of hen#hen Feiguang Biological 2roducts, --)-+

N ome 2roducts under %esearch and 2rogress of hen#hen Feiguang Biological 2roducts by the @nd of -+

N 7undraising 2rojects of hen#hen Feiguang Biological 2roducts

N %evenue and "perating Income of hen#hen Feiguang Biological 2roducts, -<)-;@

N &umber of 2lasma tations of ajor Blood 2roduct @nterprises in $hina as of (ec. -+

N 2roduction)use 2lasma Dolume of ajor Blood 2roduct @nterprises in $hina, -<)-+

N Blood 2roduct %evenue of ajor Blood 2roduct @nterprises in $hina, -)-+

N ajor ': @vents of Blood 2roduct Industry in $hina, -0)-+

N arket i#e of Blood 2roducts in $hina, -<)-;@

N =ross argin of ajor Blood 2roduct @nterprises in $hina, -)-+

Selected Charts





&ou can place your order in the olloin4 alternati/e ays:

. "rder online at www.researchinchina.com

-. 7ax order sheet to us at fax number3405 0-5+8

. @mail your order to3 report9researchinchina.com

<. 2hone us at 405 0-50-0/ 0-5+5

Party ):&ame3

:ddress3

$ontact 2erson3 Tel

@)mail3 7ax

Party B:

&ame3 Beijing Faterwood Technologies $o., Ltd >%esearchIn$hina?

:ddress3 %oom +-, Block , Tower $, $hangyuan Tiandi Building, &o. 0,u#hou treet, 1aidian (istrict, Beijing, $hina 0

$ontact2erson3

Liao Aan 2hone3

05))0-50-0

@)mail3 report9researchinchina.com 7ax3 05))0-5+8

Bankdetails3

Beneficial &ame3 Beijing Faterwood Technologies $o., LtdBank &ame3 Bank of $ommunications, Beijing BranchBank :ddress3 &". jinxiyuan shijicheng,Landianchang,1aidian(istrict,BeijingBank :ccount &o P3 5550-+5-8%outing &o P 3 -;5Bank FI7T $ode3 $"$&1BG=

itle (or5at Cost

Total

Choose type o or5at

2(7 >ingle user license? QQQQ..-,5+ O(

1ard copy QQQQQQQ.QQ. -,0 O(

2(7 >@nterprisewide license?Q....... <, O(

※Reports ill e dispatched i55ediately

once ull pay5ent has een recei/ed.

Pay5ent 5ay e 5ade y ire transer or

credit card /ia PayPal.

How to Buy



http://www.researchinchina.com/

mailto:[email protected]

mailto:[email protected]

http://www.researchinchina.com/



)out ResearchInChina

%esearchIn$hina >www.researchinchina.com? is a leading independent provider of $hina business

intelligence. "ur research is designed to meet the diverse planning and information needs of businesses,

institutions, and professional investors worldwide. "ur services are used in a variety of ways, including

strategic planning, product and sales forecasting, risk and sensitivity management, and as investment

research.

"ur Maor )cti/ities

Multi-users market reports

Database-RICDB

Custom Research

Company Search

7or any problems, please contact our service team at3


2hone3 405 0-50-0 6 7ax3 405 0-5+8 6 www researchinchina com 6 report9researchinchina com

RICDB serice

Documents

China Blood Product Industry Report, 2016-2019